What is VEGFR2?
VEGFR2 (vascular endothelial growth factor receptor 2) is a receptor tyrosine kinase expressed on vascular endothelial cells. Activation triggers Akt phosphorylation and endothelial nitric oxide synthase signalling, driving new-vessel formation. It is the most-cited receptor target in BPC-157 angiogenic-mechanism research.
What the research literature says
VEGFR2 (also designated KDR in human gene nomenclature and Flk-1 in mouse) is a receptor tyrosine kinase expressed on vascular endothelial cells. Binding of vascular endothelial growth factor (VEGF) ligands triggers receptor dimerisation and autophosphorylation, which in turn activates several downstream signalling pathways. The most characterised cascade for new-vessel-formation research runs through Akt phosphorylation to endothelial nitric oxide synthase (eNOS) activation, raising nitric oxide output and contributing to angiogenic responses.
BPC-157 research documents activation of VEGFR2 in vascular endothelial cells with receptor up-regulation following exposure (PMID 27847966). The VEGFR2-Akt-eNOS cascade is the most-replicated mechanistic finding in the BPC-157 literature and is the anchor framing for the compound’s documented effects on new-vessel formation and tissue perfusion in preclinical wound-healing models.
For TB-500 and related compounds, VEGFR2 engagement is not the primary mechanism but is a relevant secondary axis in some endothelial-cell-migration contexts. The Lv work on TB-4 angiogenesis in critical limb ischemia involves Notch/NF-κB pathway signalling that intersects with VEGFR2-axis pharmacology (PMID 32945357).
Why this matters in research context
VEGFR2 is the canonical mechanistic anchor for the BPC-157 angiogenic-research framework. Researchers studying BPC-157 pharmacology should anchor protocol design to the VEGFR2-Akt-eNOS cascade rather than treating BPC-157 effects as mechanism-agnostic. The receptor’s broader role in angiogenesis research extends well beyond the BPC-157 context — it is the central target across the anti-angiogenic pharmaceutical class (bevacizumab and related anti-VEGF biologics) and a major topic in oncology research.
Related compounds
- BPC-157 10mg — the canonical VEGFR2-engaging compound in the catalog
- VEGFR2 (glossary entry) — structure, ligands, downstream signalling
- Akt signalling (glossary entry) — downstream kinase in the cascade
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Lv S et al. Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway. Int J Mol Med 2020;46(4):1347-1358. [PMID 32945357]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.